Previous 10 | Next 10 |
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr. Jed Latkin, Chief Executive Officer, will present at th...
Navidea Biopharmaceuticals ( NAVB +9.5% ) is up on almost 50% higher volume in reaction to its announcement that an Ohio court has ruled in its favor in long-running lawsuit with lender Capital Royalty Partners (CRG). More news on: Navidea Biopharmaceuticals, Inc., Healthcare stocks ne...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Court of Common Pleas for Franklin County, Ohio (the ...
Presentation on Thursday, November 21 st at 12:25pm ET Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced tha...
Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2019 Earnings Conference Call November 7, 2019 5:00 PM ET Company Participants Jed Latkin – Chief Executive Officer Mike Rosol – Chief Medical Officer Erika Gibs – Director of Finance and Administration Conference...
Navidea Biopharm (NYSEMKT: NAVB ): Q3 GAAP EPS of -$0.17 in-line. Revenue of $0.24M (+4.3% Y/Y) Press Release More news on: Navidea Biopharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
Conference Call to be held Thursday, November 7, 2019 at 5:00 pm EDT Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today ...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, have entered a prec...
Conference Call to be held Thursday, November 7, 2019 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, to...
Cyclerion Therapeutics CYCN -70% on failed praliciguat studies . More news on: Navidea Biopharmaceuticals, Inc., Sesen Bio, Inc., IVERIC bio, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focuse...
The Company announced today that the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the NYSE American LLC upheld the NYSE Regulation staff’s previously announced determination to initiate delisting proceedings with respect to the Company’s com...